FWIW, from RVNC IR re the CB investors ":About 1/2 are major long-only investment firms, the rest are other financial institutions". "We found that the convert guys were more generalists and not typical biotech investors".
I don’t especially like the convertible-debt deal, for reasons I’ve already posted; however, the convertible-debt deal does not in any material way change my long-term* thesis for owning the stock.
*I’ve owned RVNC continuously since Feb 2016, and I intend to own it for several more years (unless the company is acquired).